Clinical Trial Update: Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing efficacy and safety of Apatinib as third-line therapy for primary pulmonary lymphoepithelioid carcinoma (lung carcinoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Carcinoma

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Guangzhou Institute of Respiratory Disease | Conditions: Lung Carcinoma | Phase 2 | Status: UNKNOWN